“…[14][15][16][17] These include a preexposure study in Thai children, 14 a preexposure study in European adults in comparison to PVRV, 15 a postexposure trial in the Phillipines, 16 a lot consistency study using a postexposure regimen, and a postexposure study in comparison to HDCV. 17 Here we report the immunogenicity and safety of CPRV in comparison to HDCV when administered as a typical preexposure schedule in healthy adults, i.e., the most commonly used regimen of the rabies vaccine in the US, in comparison to the most commonly used standard of care in the US. The primary objective of this trial was to show that all subjects receiving a three-dose standard preexposure schedule of CPRV achieved a level of virus neutralizing antibody greater than or equal to 0.5 IU/mL, the internationally accepted level of seroconversion.…”